Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity by Zhang, Dan et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Journal of Neuroinflammation
Open Access Research
Squamosamide derivative FLZ protects dopaminergic neurons 
against inflammation-mediated neurodegeneration through the 
inhibition of NADPH oxidase activity
Dan Zhang1, Xiaoming Hu1, Sung-Jen Wei2, Jie Liu3, Huiming Gao1, 
Li Qian1,4, Belinda Wilson1, Gengtao Liu5 and Jau-Shyong Hong*1
Address: 1Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, 
Research Triangle Park, NC 27709, USA, 2Laboratory of Molecular Toxicology, National Institute of Environmental Health Sciences, National 
Institutes of Health, Research Triangle Park, NC 27709, USA, 3Inorganic Carcinogenesis, Laboratory of Comparative Carcinogenesis, NCI at 
NIEHS, Research Triangle Park, North Carolina 27709, USA, 4Comprehensive Center for Inflammatory Disorders, University of North Carolina, 
Chapel Hill, NC 27599, USA and 5Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking 
Union Medical College, 1 Xian Nong Tan Street, Beijing 100050, ProC
Email: Dan Zhang - zhangd2@niehs.nih.gov; Xiaoming Hu - hux2@niehs.nih.gov; Sung-Jen Wei - wei2@niehs.nih.gov; 
Jie Liu - liu6@niehs.nih.gov; Huiming Gao - gao2@niehs.nih.gov; Li Qian - qianl2@niehs.nih.gov; Belinda Wilson - wilson3@niehs.nih.gov; 
Gengtao Liu - liugt@imm.ac.cn; Jau-Shyong Hong* - hong3@niehs.nih.gov
* Corresponding author    
Abstract
Background: Inflammation plays an important role in the pathogenesis of Parkinson's disease (PD) through over-
activation of microglia, which consequently causes the excessive production of proinflammatory and neurotoxic factors,
and impacts surrounding neurons and eventually induces neurodegeneration. Hence, prevention of microglial over-
activation has been shown to be a prime target for the development of therapeutic agents for inflammation-mediated
neurodegenerative diseases.
Methods: For in vitro studies, mesencephalic neuron-glia cultures and reconstituted cultures were used to investigate
the molecular mechanism by which FLZ, a squamosamide derivative, mediates anti-inflammatory and neuroprotective
effects in both lipopolysaccharide-(LPS)- and 1-methyl-4-phenylpyridinium-(MPP+)-mediated models of PD. For in vivo
studies, a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-(MPTP-) induced PD mouse model was used.
Results: FLZ showed potent efficacy in protecting dopaminergic (DA) neurons against LPS-induced neurotoxicity, as
shown in rat and mouse primary mesencephalic neuronal-glial cultures by DA uptake and tyrosine hydroxylase (TH)
immunohistochemical results. The neuroprotective effect of FLZ was attributed to a reduction in LPS-induced microglial
production of proinflammatory factors such as superoxide, tumor necrosis factor-α (TNF-α), nitric oxide (NO) and
prostaglandin E2 (PGE2). Mechanistic studies revealed that the anti-inflammatory properties of FLZ were mediated
through inhibition of NADPH oxidase (PHOX), the key microglial superoxide-producing enzyme. A critical role for
PHOX in FLZ-elicited neuroprotection was further supported by the findings that 1) FLZ's protective effect was reduced
in cultures from PHOX-/- mice, and 2) FLZ inhibited LPS-induced translocation of the cytosolic subunit of p47PHOX to the
membrane and thus inhibited the activation of PHOX. The neuroprotective effect of FLZ demonstrated in primary
neuronal-glial cultures was further substantiated by an in vivo study, which showed that FLZ significantly protected against
MPTP-induced DA neuronal loss, microglial activation and behavioral changes.
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Conclusion: Taken together, our results clearly demonstrate that FLZ is effective in protecting against LPS- and MPTP-
induced neurotoxicity, and the mechanism of this protection appears to be due, at least in part, to inhibition of PHOX
activity and to prevention of microglial activation.
Background
Accumulating evidence indicates that chronic inflamma-
tion plays a critical role in the pathogenesis of many neu-
rodegenerative diseases such as Alzheimer's disease (AD)
[1], Parkinson's disease (PD) [2], multiple sclerosis [3]
and macular degeneration [4]. Inflammation in the brain
is characterized by over-activation of microglia [5], the
resident immune cells in the central nervous system,
resulting in dysregulated inflammatory processes. Activa-
tion of microglia in the substantia nigra (SN) of PD
patients was first reported in 1988 [6]. The presence of
activated microglia in the SN has also been observed in
animal models of PD [7], which include direct adminis-
tration of the inflammagen lipopolysaccharide (LPS) into
the brain [8]. Inhibition of the glial over-reaction and the
inflammatory processes may thus represent a prime target
for the development of novel therapeutic agents for these
neurodegenerative diseases.
Annona glabra is a tropical fruit tree, the leaf and root of
which have been used as traditional Chinese medicines.
Recently, several effective components have been isolated
from Annona glabra and found to have biological activities
such as anti-cancer and anti-apoptosis effects [9,10].
Among these, a natural squamosamide from annona gla-
bra  has been isolated and found to have anti-oxidant
activity [11]. After chemical structure modification, a
cyclic analogue of this squamosamide with stronger anti-
oxidant activity was synthesized as N-[2-(4-hydroxy-phe-
nyl)-ethyl]-2-(2, 5-dimethoxy-phenyl)-3-(3-methoxy-4-
hydroxy-phenyl)-acrylamide, and this novel synthetic
compound was named FLZ (Fig. 1). We have previously
shown that FLZ has protective effects against neuronal
damage and neuronal death induced by hydrogen perox-
ide, glutamate, N-methyl-d-asparatate, hemoglobin and
ischemia-reoxygenation [12-14]. Although our previous
reports demonstrated the neuroprotective effect of FLZ,
the role of microglia in this FLZ-elicited neuroprotection
and the molecular mechanisms underlying the protective
actions of FLZ were not studied. The purpose of this study
was to delineate the role of inflammation in FLZ-induced
neuroprotection.
In this study, LPS-induced degeneration of dopaminergic
(DA) neurons in mesencephalic neuronal-glial cultures
was used as an in vitro model for studying the role of
microglia in the therapeutic effect of FLZ [15-17]. In this
model, LPS directly induces microglial over-activation
with subsequent release of a large amount of proinflam-
matory factors that damage neurons [15]. Here we show
that the neuroprotective effect of FLZ is attributable to a
reduction in LPS-induced microglial production of proin-
flammatory factors, such as superoxide, tumor necrosis
factor-α (TNF-α), nitric oxide (NO) and prostaglandin E2
(PGE2). Mechanistic studies revealed that the anti-inflam-
matory properties of FLZ are mediated through inhibition
of nicotinamide adenine dinucleotide phosphate oxidase
(NADPH oxidase, also called PHOX), the key microglial
superoxide-producing enzyme. Finally, animal studies
showed that FLZ significantly protects against 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced DA




Timed-pregnant Fisher F344 rats were obtained from
Charles River Laboratories (Raleigh, NC). Eight-week-old
The chemical structure of FLZ Figure 1
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male C57BL/6J mice, weighing 25–28 g, were maintained
on a 12:12 h light:dark cycle and fed ad libitum. PHOX-
deficient (gp91 PHOX-/-) and wild-type C57BL/6J (gp91
PHOX+/+) mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME). Animals were adapted for 2 weeks
to the conditions described above before experimenta-
tion. To examine the effect of FLZ on MPTP-induced neu-
rotoxicity, mice received daily MPTP injections [15 mg/kg
of MPTP.HCl, s.c.] for 6 consecutive days. From the third
day on, FLZ (75 mg/kg, p.o.) was administered 30 min
before every MPTP injection for the last 4 days. Housing,
breeding, and experimental use of the animals were per-
formed in strict accordance with the National Institutes of
Health guidelines.
Reagents
FLZ was kindly provided by Professor Xiaotian Liang in
the Department of Pharmaceutical Chemistry, Institute of
Materia Medica, Chinese Academy of Medical Science. It is
a white powder with 99% purity. The polyclonal anti-tyro-
sine hydroxylase (TH) antibody was a generous gift from
Dr. John Reinhard (GlaxoSmithKline, Research Triangle
Park, NC). LPS (strain O111:B4) and 2', 7'-dichlorofluo-
rescin diacetate were purchased from Calbiochem (San
Diego, CA). [3H]-DA (28 Ci/mmol) was purchased from
PerkinElmer Life Sciences Inc. (Boston, MA). The mouse
monoclonal antibody raised against OX42 antigen was
purchased from Chemicon International (Temecula, CA).
Rabbit anti-p47phox was obtained from Millipore Corpora-
tion (Bedford MA). FITC-conjugated goat anti-rabbit IgG
antibody was obtained from Jackson ImmunoResearch
Laboratories Inc. (West Grove, PA). Rabbit anti-GAPDH
antibody was obtained from Abcam (Cambridge, MA).
Mouse anti-gp91phox antibody was purchased from BD
Transduction Laboratories (San Jose, CA). All other rea-
gents came from Sigma (St Louis, MO).
Cell cultures
Primary rat mesencephalic neuronal-glial cultures were
prepared as described previously [18]. Briefly, after the
ventral mesencephalic tissues were removed and dissoci-
ated by a mechanical triturating, cells were seeded at 5 ×
105/well to 24-well culture plates or 1.5 × 105/well to 96-
well culture plates in maintenance medium. Seven-day-
old cultures were used for treatment. Immunocytochemi-
cal analysis indicated that at the time of treatment the cul-
tures were made up of ~10% microglia, ~50% astroglia,
and ~40% neurons, of which 1 ~2% were TH-immunore-
active neurons.
Primary microglia-enriched cultures were prepared from
the whole brains of 1 or 2-day-old mice, as described pre-
viously [19]. Briefly, brain tissues, devoid of meninges
and blood vessels, were dissociated by mechanical tritura-
tion. The isolated cells (5 × 107) were seeded in 150 cm2
culture flasks in Dulbecco's modified Eagle medium.
Upon reaching confluence (12–14 days), microglia were
separated from astroglia by shaking the flasks at 180 rpm
for 1 h. Purity of the microglia-enriched cultures was
>98%, as determined by immunocytochemical staining.
The rat microglia HAPI cells were generous gifts from Dr.
James R. Connor (Pennsylvania State University, Hershey,
PA). They were maintained at 37°C in Dulbecco's modi-
fied Eagle's medium supplemented with 10% fetal bovine
serum, 50 U/ml penicillin, and 50 μg/ml streptomycin in
a humidified incubator with 5% CO2/95% air.
DA uptake assay
Degeneration of DA neurons was assessed by measuring
the ability of cultures to take up DA. DA uptake assays
were performed as previously described [18]. Briefly, after
two washes with warm Krebs-Ringer buffer the cultures
were incubated for 20 min at 37°C with 1 μM [3H]-DA for
DA uptake. Then the cultures were washed 3 times with
ice-cold KRB, and the cells were then dissolved in 1 N
NaOH. Radioactivity was determined by liquid scintilla-
tion counting. Nonspecific DA uptake, determined in the
presence of mazindol (10 μM), was subtracted.
Immunocytochemistry
DA neurons were recognized with an anti-TH antibody,
and microglia were detected with the OX-42 antibody, as
described previously. For morphological analysis, images
were acquired using an inverted microscope (Nikon,
Tokyo, Japan) connected to a camera (DAGE-MTI, Michi-
gan City, IN) operated with the MetaMorph software
(Universal Imaging Corporation, Downingtown, PA). To
quantify cell numbers, total TH positive cells in entire
wells were counted by three individuals. The average of
these scores was reported.
Assay for inflammatory factors
For the TNF-α assay, culture supernatant was collected
after 3 h of stimulation with LPS. The concentration of
TNF-α was measured with a mouse TNF-α enzyme-linked
immunosorbent assay kit from Genzyme (Cambridge,
MA).
The production of NO was assessed as the accumulation
of nitrite in the culture supernatant, using a colorimetric
reaction with the Griess reagent. The culture supernatants
were collected after 24 h of stimulation with LPS and
mixed with equal volumes of the Griess reagent. The
absorbance at wavelength 540 nm was measured with a
UV MAX kinetic microplate reader (Molecular Devices).
The production of PGE2 in the enriched microglial cul-
tures was evaluated 24 h after LPS treatment using a PGE2Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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EIA kit from Cayman (Ann Arbor, MI), according to the
manufacturer's instructions.
Assay for reactive oxygen species (ROS)
Production of superoxide was determined by measuring
the superoxide dismutase (SOD)-inhibitable reduction of
the water-soluble tetrazolium salt (WST-1) 30 min after
LPS treatment [20]. Microglia-enriched cultures in 96-well
culture plates were washed twice with Hanks' Balanced
Salt Solution (HBSS) without phenol red. Cultures were
then incubated at 37°C for 1 h with vehicle control or FLZ
in HBSS (50 μl/well). Then, 50 μl of HBSS with and with-
out SOD (50 U/ml) was added to each well along with 50
μl of WST-1 (1 mM) in HBSS and 50 μl of vehicle or LPS
(2 ng/ml). Thirty minutes later, the absorbance at 450 nm
was read with a SpectraMax Plus microplate spectropho-
tometer (Molecular Devices, Sunnyvale, CA).
The production of intracellular ROS was measured by 2',
7'-dichlorofluorescin diacetate oxidation 2 h after LPS
treatment. Microglia-enriched cultures were seeded (5 ×
104) in 96-well plates and then exposed to 20 μM 2', 7'-
dichlorofluorescin diacetate for 1 h, followed by pretreat-
ment with FLZ for 1 h and treatment with HBSS contain-
ing LPS. After incubation, the fluorescence was read at the
485 nm excitation and 530 nm emission on a fluores-
cence plate reader. Cell-free experiments with and without
FLZ were conducted to determine that the reagents them-
selves did not alter fluorescence.
Real-time RT-PCR analysis
The primers synthesized from Sigma Genosys were used
as follows: TNF-α, forward (TCGTAGCAAACCAC-
CAAGCA) and reverse (CCCTTGAAGAGAACCT-
GGGAGTA); iNOS, forward
(GTGCTAATGCGGAAGGTCATG) and reverse (CGCTTC-
CGACTTTCCTGTCT); COX2, forward (CCAGCAGGCT-
CATACTGATAGGA) and reverse
(GCAGGTCTGGGTCGAACTTG); GAPDH, forward (CCT-
GGAGAAACCTGCCAAGTAT) and reverse (AGCCCAG-
GATGCCCTTTAGT); and gp91, forward
(CCTGCAGCCTGCCTGAATT) and reverse (AAGGAGAG-
GAGATTCCGACACA).
Flow cytometry
HAPI cells were treated with 10 ng/ml LPS for 24 h in the
presence or absence of 10 μM FLZ. The cells were removed
from culture and washed twice with cold FACS buffer
(saline with 5% normal goat serum). Cells were incubated
with FcR block for 30 min at 4°C and then incubated for
45 min at 4°C with PE-conjugated OX6 antibody or the
appropriate isotype control antibody (BD Pharmingen).
After antibody binding, cells were washed and fixed. Flu-
orescence was analyzed on a FACSCalibur (BD Bio-
sciences). The mean fluorescent intensity (MFI) of
experimental group was determined by subtracting the
MFI of the isotype control from the MFI of the unstimu-
lated or LPS-stimulated microglia.
Subcellular fractionation and western blot analysis
Subcellular fractionation was performed as described pre-
viously [21]. HAPI cells, seeded in dishes at 5 × 104 cells/
well, were treated with 10 ng/ml LPS for 10 min in the
absence or presence of 10 μM FLZ for 1 h. The cells were
then lysed in hypotonic lysis buffer, incubated on ice for
30 min, and subjected to Dounce homogenization (~20–
25 strokes, tight pestle A). The lysates were loaded onto
sucrose in lysis buffer and centrifuged at 1,600 g for 15
min; the supernatant above the sucrose gradient was used
as the cytosolic fraction after centrifugation at 150,000 g
for 30 min. The pellets, solubilized in 1% Nonidet P-40
hypotonic lysis buffer, were used as the membranous frac-
tion. For western blot analysis, the primary antibodies
included anti-p47phox (1: 2000), anti-GAPDH (1:2000)
and anti-gp91phox (1:2000).
Rota-rod measurement
Quantitative measurements of motor coordination in
mice were performed using an accelerating rota-rod
(model 7650, UGO Basile, Comerio, VA, Italy). The rota-
rod consisted of a plastic rod (diameter = 3 cm; length =
30 cm) partitioned off with round plates to prevent the
mice from escaping from the sides of the rod. The rod was
covered with smooth plastic tubing and suspended 16 cm
above five plastic levers attached to timers that stop when
mice land on the lever surface. The mice were placed on
the rod that rotated at 3 rpm at 0 min and accelerated
from 4 to 20 rpm over 5 min. Mice were oriented perpen-
dicular to the long axis of the rod, such that the mice had
to make forward walking movements to avoid falling. The
latency time to fall was measured using mice 28 days after
their first dose of MPTP, with each mouse experiencing
three trials per day with an intertrial interval of 10 min.
The average latency of each mouse was calculated.
Immunohistochemistry and cell counting in the SNpc of 
C57BL/6 mice
Mouse brains were cut on a horizontal sliding microtome
into transverse free-floating sections, 35 μm in thickness.
Six to eight brain sections of SNpc were collected at inter-
vals of 140 μm. For immunohistochemistry, the following
concentrations of antibodies were used: anti-TH (1:5000),
anti-Iba-1 (1: 1000), biotinylated anti-mouse IgG
(1:1000). Digital images of TH neurons in SNpc were
acquired on an Olympus microscope (Olympus®, Tokyo,
Japan) using an attached Polaroid digital microscope
camera (Polaroid®, Cambridge, MA, USA). Twenty four
consecutive brain slices (35-μm thickness), which encom-
passed the entire substantia nigra compacta, were col-
lected. A normal distribution of the number of TH-IRJournal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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neurons in the SNpc was constructed based on the counts
of 24 slices from saline-treated mice, MPTP-treated mice
and FLZ-treated mice. The distribution curves from these
groups superimpose and show no difference in number
and shape of the curves. Six to eight evenly spaced brain
slices from different groups of animals were immunore-
acted using an antibody against TH, and immunoreactive
cells were counted. The distribution of cell numbers from
each animal was matched with the normal distribution
curve to correct for errors resulting from the cutting. Three
individuals performed counting in a double-blind man-
ner. Conclusions were drawn only when the interobserver
differences were within 5%. A mean value for the number
of SNpc TH neurons was then deduced by averaging the
counts of 6–8 sections for each animal.
Statistical analysis
The data are presented as mean ± S.E.M. For multiple
comparisons of groups, two-way ANOVA was used. Statis-
tical significance of differences between groups was
assessed using paired Student's t test, followed by Bonfer-
roni correction using the JMP program (SAS Institute,
Cary, NC, USA). A value of P < 0.05 was considered statis-
tically significant.
Results
FLZ protects DA neurons against LPS-induced 
degeneration
Mesencephalic neuronal-glial cultures were pretreated
with FLZ or vehicle for 1 h, or post-treated with 10 μM FLZ
at 0, 0.5, 1, 2 and 3 h after LPS treatment. Seven days later,
the degeneration of DA neurons was assessed. [3H]DA
uptake assays indicated that LPS treatment reduced the
uptake capacity to about 40% of that of vehicle-treated
control cultures (Fig. 2A). FLZ attenuated LPS-induced DA
uptake decreases in a dose-dependent manner; whereas
10 μM FLZ alone did not affect DA uptake in cultures.
Morphologically, in addition to reductions in the abun-
dance of TH neurons, the dendrites of the remaining TH
neurons in LPS-treated cultures were significantly less
elaborate than those in the control group (Fig. 2B). FLZ
significantly attenuated these morphological changes in
TH neurons induced by LPS. These protective effects of
FLZ were confirmed by the cell count numbers of TH neu-
rons (Fig. 2C). For the post-treatment groups, 10 μM FLZ
showed a protective effect even when given 2 h after LPS
treatment (Fig. 2D). However, when 10 μM FLZ was
added at 3 h post-LPS treatment, no significant protective
effect was observed.
FLZ's neuroprotective effect against LPS-induced DA 
neurotoxicity is mediated through microglia
In addition to neurons, the mesencephalic neuron-glia
cultures also contain ~10% microglia and ~50% astro-
cytes. To evaluate the potential contribution of glia in
mediating the neuroprotective effect of FLZ, we per-
formed cell reconstitution experiments. As shown in Fig 3,
1-methyl-4-phenylpyridine (MPP+) reduced DA uptake by
about 52% in neuronal-glial cultures, but 10 μM FLZ sig-
nificantly protected neurons against this damage. How-
ever, 10 μM FLZ failed to show any protective effect
against the toxicity of MPP+ in microglia-depleted cul-
tures, which contain only neurons and astrocytes. In con-
trast, when 10% microglia were added back to the
neuron-enriched cultures, the MPP+-induced reduction in
DA uptake could be reversed by 10 μM FLZ. These results
demonstrate that microglia, but not astroglia, mediate
FLZ's neuroprotective effect against LPS-induced neurode-
generation.
FLZ suppresses LPS-induced microglia activation
Immunohistochemical studies using the OX-42 antibody,
a marker for rat microglia, showed LPS-induced morpho-
logical evidence of microglial activation in mesencephalic
neuronal-glial cultures. LPS treatment transformed micro-
glia from a predominantly resting, round, small cell mor-
phology to an activated, rod- and/or amoeboid-shaped
cell morphology with intensified immunoreaction (Fig.
4A). LPS-stimulated activation of microglia was partially
suppressed by pretreating the cultures with 10 μM FLZ,
whereas the same concentration of FLZ alone did not
show significant effects on microglial morphology. The
effect of FLZ on activated microglia was further confirmed
by flow cytometric analysis using an anti-MHC-II anti-
body, a marker for the activated microglia. Quantitative
analysis revealed that the degree of 10 ng/ml LPS-induced
activation of microglia was decreased by 60% by pretreat-
ment with 10 μM FLZ (Fig. 4B). Rat HAPI-immortalized
microglial cells were used for this flow cytometric analysis
because most of the primary microglial cells died during
the experimental procedure.
FLZ suppresses LPS-induced release of proinflammatory 
mediators and their gene expression
Accumulating evidence indicate that proinflammatory
factors released by over-activated microglia in dysregu-
lated inflammatory conditions play a key role in DA neu-
rodegeneration [18,19,22]. Therefore, we hypothesized
that FLZ would dampen LPS-stimulated production of
proinflammatory factors in microglia-enriched cultures.
We found that pretreatment with FLZ at concentrations
ranging from 2.5 to 10 μM significantly blocked LPS-stim-
ulated production of proinflammatory mediators and
their mRNA expression in a dose-dependent manner.
These gene products include TNF-α (Fig. 5A and 5B),
inducible nitric oxide synthase (iNOS) (Fig. 5C and 5D),
and COX-2 (Fig. 5E and 5F). In addition, FLZ significantly
attenuated LPS-induced ROS production including extra-
cellular superoxide (Fig. 5G) and intracellular ROS (Fig.
5H).Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
Page 6 of 13
(page number not for citation purposes)
FLZ protects against LPS-induced neuronal degeneration 
through inhibition of PHOX activation
Among the proinflammatory factors released from over-
activated microglia, production of superoxide from PHOX
has been shown to exert direct neurotoxicity and to regu-
late gene expression for other proinflammatory factors
[19]. To further investigate the role of ROS in FLZ-elicited
neuroprotective effects, we used neuronal-glial cultures
from mice deficient in the catalytic subunit (gp91PHOX) of
PHOX, which is the key enzyme required for the produc-
tion of ROS. As shown in Fig. 6A, LPS treatment of neuro-
nal-glial cultures prepared from PHOX+/+  mice
substantially reduced [3H]-DA uptake and, similarly, FLZ
attenuated this decrease. In contrast, LPS treatment also
showed a significant but smaller reduction in [3H]-DA
uptake capacity in cultures from PHOX-/-  mice, while
FLZ's protective effect was reduced significantly. Further,
results from real-time PCR showed that FLZ inhibited the
gp91 mRNA expression induced by LPS treatment (Fig.
6B). Therefore, our data support the idea that PHOX plays
an important role in FLZ-mediated protection against
LPS-induced neuronal degeneration.
It has been reported that activation of PHOX holoenzyme
is required to initiate the translocation of its cytosolic
components p47phox  into the plasma membrane [23].
FLZ functionally and morphologically protects DA neurons from LPS-induced neurotoxicity in rat mid-brain neuron-glia culture Figure 2
FLZ functionally and morphologically protects DA neurons from LPS-induced neurotoxicity in rat mid-brain 
neuron-glia culture. Neuronal-glial cultures were pre-treated with different concentrations of FLZ for 1 h followed by 2 ng/
ml LPS; 7 days later, DA neurotoxicity was measured by [3H]-DA uptake assay (A) and by immunocytochemical analysis. Rep-
resentative pictures of immunoreactions are shown in (B) and TH neuron counts are shown in (C). For assessment of FLZ 
treatment following neurotoxic insult, neuronal-glial cultures were first treated with 2 ng/ml LPS. Then, 0, 0.5, 1, 2, and 3 h 
later, 10 μM FLZ was added to the cultures. DA neurotoxicity was measured by [3H]-DA uptake assay 7 days later (D). The 
data are expressed as percentages of control culture values, and represent the mean ± S.E.M. for three independent experi-
ments, each performed with triplicate samples. ## p < 0.01 and ### p < 0.001 compared with vehicle-treated control cultures; 
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared to LPS treatment group. Scale bar, 100 μm.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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Because of the potent inhibition of ROS production by
FLZ, we sought to determine whether FLZ inhibits PHOX
activation by preventing this translocation. Data from
subcellular fractionation and western blot analysis clearly
showed an increase in immunoreactivity of p47phox in the
membrane of microglia 10 min after LPS treatment (Fig.
6C), and this increase in immunoreactivity was signifi-
cantly blocked in the presence of FLZ. Thus, this result fur-
ther proves that FLZ-mediated inhibition of superoxide
production by LPS is mediated through suppression of
p47phox  membrane translocation; that is, activation of
PHOX.
FLZ inhibits MPTP-induced DA neurotoxicity, microglial 
activation and motor function deficiency in mice
To further substantiate the neuroprotective effect of FLZ
shown in these cell culture studies, we performed an ani-
mal study with daily injections of MPTP for 6 days.
Immunohistochemical analysis (Fig. 7A) revealed that
MPTP injection caused significant DA neuronal loss in
SNpc. Both number of DA neurons and extent of neuronal
processes were significantly lost in MPTP-treated group
mice. For a second group, FLZ was given to the mice start-
ing on the third day of MPTP treatment and injections of
FLZ were continued daily for the next four days. This post-
treatment regimen with FLZ significantly reduced MPTP-
induced DA neuronal loss. Cell count analysis showed
that MPTP treatment decreased the number of DA neu-
rons in the SNpc to about 45% of the vehicle treated
group, while post-treatment with FLZ increased the
number of remaining neurons to about 75% of the vehi-
cle-treated group. For a third group of mice that received
only FLZ, the number of DA neurons did not differ from
the vehicle-treated group (Fig. 7B). Morphological
changes of microglia revealed by immunoreaction with
Iba-1 antibody were used as an index for inflammatory
conditions. MPTP treatment transformed most of the
microglia from resting cells to activated, large cells, and
this activation of microglia was significantly suppressed
by FLZ post-treatment (Fig. 7C). To obtain quantitative
data, the midbrains of the mice were dissected out and
changes in Iba-1 immunoreactivity were determined
using western blot assays. The results confirmed that FLZ
suppressed MPTP-induced microglial activation (Fig. 7D).
To access the locomotor activities of the mice, the rota-rod
test was used. At 28 days after the first MPTP injection, the
length of time that MPTP-group mice remained on the rod
was much less than that of vehicle-group mice, while post-
treatment with FLZ significantly prolonged the time that
the mice were able to remain on the rod (Fig. 7E). These
results from rota-rod testing thus corroborated the immu-
nohistochemical results showing loss of DA neurons.
Discussion
In this study, we demonstrate that FLZ significantly
reduces LPS-induced degeneration of DA neurons in pri-
mary mesencephalic neuronal-glial cultures, as evidenced
by DA uptake and TH immunoreaction of DA neurons.
Furthermore, post-treatment with FLZ, 2 h after LPS chal-
lenge, was still effective in providing neuroprotection.
Mechanistic studies revealed that inhibition of microglial
PHOX activation by FLZ underlay the neuroprotective
effect of FLZ. Reduction of PHOX-generated superoxide
was a critical initial site of action of FLZ, which in turn
resulted in suppression of a wide array of proinflamma-
tory mediators. In animal studies, FLZ significantly amel-
iorated MPTP-induced DA neuronal loss in SNc and
motor function deficits even when administered 2 days
after MPTP intoxication.
In the brain, two types of glial cells, astroglia and micro-
glia, are the main players in the neuroinflammatory proc-
ess [24]. Astroglia serve to maintain homeostasis and
secrete neurotrophic factors that promote neuronal sur-
vival. Microglia, on the other hand, play a role in immune
surveillance under normal conditions, and become read-
ily activated in response to infections and neuronal inju-
ries under pathological conditions [25]. Microglial pro-
inflammatory factors such as NO, TNF-α, PGE2 and ROS
serve immune surveillance functions by killing foreign
microorganisms [26]. However, over-activation of micro-
glia results in overproduction of proinflammatory factors,
which in turn results in neuronal death in the brain [27-
Microglia (but not astroglia) mediate the neuroprotection of  FLZ Figure 3
Microglia (but not astroglia) mediate the neuropro-
tection of FLZ. Different kinds of cultures were pretreated 
with 10 μM FLZ for 1 h, and then 0.25 μM MPP+ was added. 
DA neurotoxicity was measured by [3H]-DA uptake assay 7 
days later. The data are expressed as percentages of control 
culture values, and represent the mean ± S.E.M. for three 
independent experiments, each performed with triplicate 
samples. ### p < 0.001 compared with vehicle-treated con-
trol cultures; *** p < 0.001 compared to MPP+ treatment 
group.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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29]. It is generally accepted that neuroinflammation gen-
erated by dysregulated microglia plays a critical role in
neurodegenerative disorders, such as PD. We and others
have documented that microglial proinflammatory and
neurotoxic factors such as free radicals, cytokines, chem-
okines, and prostaglandins may damage surrounding
neurons and cause neurodegeneration [19,22,30,31].
Hence, agents that can inhibit the production of proin-
flammatory and neurotoxic factors may be highly desira-
ble candidates for the development of potential
therapeutic agents. In this study, we show that FLZ signif-
icantly inhibits microglial activation and microglial pro-
duction of proinflammatory factors, as well as the
generation of free radicals such as superoxide anion and
iROS, and we show corresponding changes at both the
mRNA and protein levels. This study provides strong evi-
dence to indicate that the inhibitory effect of FLZ on the
production of these factors is a major mechanism in its
significant protection of DA neurons against inflamma-
tion-mediated degeneration.
FLZ attenuates LPS-induced microglia activation Figure 4
FLZ attenuates LPS-induced microglia activation. (A): Neuronal-glial cultures were pretreated with 10 μM FLZ for 1 h 
followed by 2 ng/ml LPS; 24 h later, activation of microglia was assessed by OX-42 immunohistochemistry. Representative 
results are illustrated. (B): HAPI microglia cells were pretreated with 10 μM FLZ for 1 h followed by stimulation with 10 ng/ml 
LPS for 24 h. Expression of MHC class II antigen was detected by flow cytometry. The cells were analyzed on a FACS Calibur, 
and the MFI of experimental groups was determined by subtracting the MFI of the isotype control from the MFI of each group. 
The data are expressed as mean ± S.E.M. for three independent experiments, each performed with triplicate samples. ## p < 
0.01 compared with vehicle-treated control group; * p < 0.05 compared to LPS treatment group. Scale bar, 50 μm.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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FLZ inhibites LPS-induced production of proinflammatory factors and their gene expression in microglia Figure 5
FLZ inhibites LPS-induced production of proinflammatory factors and their gene expression in microglia. The 
effects of FLZ on LPS-induced production of TNF-α, NO, and PGE2 (A, C, E, respectively) or TNF-α, iNOS, and COX-2 
mRNA expression (B, D, F, respectively) and the production of superoxide (G), and intracellular ROS (H) are shown. 
Enriched microglia cells were treated with different concentrations of FLZ or with vehicle for 1 h before addition of 2 ng/ml 
LPS. For mRNA analysis, total RNA was harvested 3 h after LPS treatment, followed by real-time RT-PCR analysis of iNOS, 
TNF-α, COX-2 and GAPDH using specific primers. The data are expressed as mean ± S.E.M. for three independent experi-
ments, each performed with triplicate samples. ## p < 0.01 and ### p < 0.001 compared with vehicle-treated control cultures; 
* p < 0.05, ** p < 0.01 and *** p < 0.001 compared to LPS treatment group.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
Page 10 of 13
(page number not for citation purposes)
Among the various factors released from microglia, super-
oxide generated by PHOX plays the most critical role in
the subsequent neuroinflammatory processes and neuro-
degeneration by producing direct damage to DA neurons
and promoting the production of other proinflammatory
factors [31-33]. Activation of PHOX in microglia not only
increases the production of superoxide but indirectly
increases intracellular ROS concentrations, possibly
through conversion of superoxide to H2O2, which is
membrane permeable. Increases in intracellular ROS can
enhance activation of NF-κB, which would lead to higher
TNF-α and PGE2 production [19,26]. In addition, it has
been reported that PHOX inhibitors prevent LPS/IFNγ-
induced degradation of IκBα, and thus inhibit activation
of NF-κB [34]. Thus, PHOX is an ideal target for develop-
ing anti-inflammatory drugs due to its dual roles in
inflammation-related neuronal damage, and due to its
high degree of cell-type specificity in immune cells such as
microglia, macrophages, and neutrophils [19,22].
The fact that FLZ significantly inhibits the production of
superoxide induced by LPS led us to examine this notion
in greater detail by using PHOX-/-deficient mutant mice.
The finding that FLZ could significantly lessen LPS-
induced DA uptake reduction in cells from wild-type
mice, but its protective effect is less significant in cultures
Microglial PHOX is the target of FLZ's inhibition in LPS-induced neurotoxicity Figure 6
Microglial PHOX is the target of FLZ's inhibition in LPS-induced neurotoxicity. (A): The role of PHOX in FLZ's 
protective effect. PHOX+/+ and PHOX-/- mouse neuronal-glial cultures were pretreated with vehicle or with 10 μM FLZ for 1 
h, followed by 10 ng/ml LPS treatment. Neurotoxicity was assessed by [3H]-DA uptake 7 days later. (B): The effect of FLZ on 
LPS-induced gp91 mRNA expression. Enriched microglia cells were treated with vehicle or with different concentrations of 
FLZ for 1 h before the addition of 2 ng/ml LPS. For mRNA analysis, total RNA was harvested 3 h after LPS treatment, followed 
by real-time reverse transcription-PCR analysis using specific primers. (C): Effect of FLZ on cytosolic p47phox protein transloca-
tion. HAPI cells were pretreated with vehicle or with 10 μM FLZ for 1 h followed by 10 ng/ml LPS treatment for 10 min. Sub-
cellular fractions were isolated to perform western blot analysis. C = cytosolic extract; M = membrane extract. GAPDH and 
gp91phox are used as internal cytosolic and membrane controls, respectively. The data are expressed as percentages of control 
culture values and represent the mean ± S.E.M. for three independent experiments, each performed with triplicate samples. ## 
p < 0.01 and ### p < 0.001 compared with vehicle-treated control group; * p < 0.05 and ** p < 0.01 compared to LPS treat-
ment group.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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from PHOX-/- mice, strongly support the contention that
the protective effect of FLZ is probably mediated through
inhibition of PHOX activity.
Since these results pointed to the importance of FLZ/
PHOX interactions, we further studied the molecular
mechanism underlying inhibition of PHOX by FLZ.
PHOX is a multicomponent complex, dormant in non-
activated cells, that catalyzes during phagocytosis and
increases the production of superoxide anion O2
-. The oxi-
dase is composed of a membrane-bound heterodimeric
flavocytochrome, consisting of two subunits, gp91phox
FLZ shows significant protective effect against the toxicity of MPTP in vivo Figure 7
FLZ shows significant protective effect against the toxicity of MPTP in vivo. Eight-week-old male C57BL/6J mice 
received daily MPTP injections (15 mg/kg, s.c.) for 6 consecutive days. From the third day on, FLZ (75 mg/kg, p.o.) was admin-
istered 30 min before every MPTP injection for the last 4 days. DA neurotoxicity was measured by immunohistochemistry 
using an anti-TH antibody (A) and cell counting of DA neurons (B) in the SNpc of different groups of mice. To assess activa-
tion of microglia, SNpc brain sections were stained using Iba-1 antibody, a microglial maker (C). To obtain quantitative data, 
the midbrains of the mice were dissected out, and levels of Iba-1 in these midbrains were determined using western blot assays 
(D). To assess the protective effect of FLZ on MPTP-induced motor function deficiency, a rotor-rod assay was used and the 
time for each mouse to remain on the spinning rod was recorded (E). The data are expressed as mean ± S.E.M. for the results 
of 6–8 mice. # p < 0.05 and ## p < 0.01 compared with vehicle-treated control group; * p < 0.05 compared to MPTP treat-
ment group. Scale bar, 50 μm.Journal of Neuroinflammation 2008, 5:21 http://www.jneuroinflammation.com/content/5/1/21
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and p22phox, four cytosolic subunits, p47phox, p67phox,
p40phox, and the small GTPase Rac. All of the redox sta-
tions of the oxidase are located on gp91phox and, in the
resting state, are not engaged in electron transport. O2
-
production is, most likely, the result of a conformational
change in gp91phox, consequent to the translocation of
cytosolic components to the membrane environment,
and the interaction of one or more components with cyto-
chrome b559, a process termed oxidase assembly [35,36].
Western blot analysis from this study revealed that FLZ
inhibited LPS-induced p47phox translocation from cytosol
to membrane. Thus, FLZ inhibited the activation of PHOX
by inhibiting its assembly, thereby inhibiting the activa-
tion of microglia and the production of various proin-
flammatory factors and subsequently resulting in a
neuroprotective effect.
The neuroprotective effect of FLZ shown in our cell culture
studies was further confirmed in animal studies using
MPTP as a neurotoxin. Reactive microgliosis after MPTP
treatment has been documented by our laboratory and
others [33,37]. It is believed that the initial damage to or
death of DA neurons caused by MPTP could signal the
activation of microglia through either the release of solu-
ble factors from damaged neurons or the loss of cell-cell
contact inhibition between neurons and microglia
[30,38,39]. Reactive microgliosis may release additional
proinflammatory and neurotoxic factors to augment the
neuroinflammatory process and cause further damage to
the remaining DA neurons. Thus, the continuing proc-
esses involving death of DA neurons, secondary activation
of microglia (reactive microgliosis), and further neuronal
damage would create a vicious "self-propelling" circle and
trigger progressive neurodegeneration [15,26]. We find
that FLZ significantly prevents DA neuronal loss in SNpc
after MPTP treatment. The efficacy of neuroprotection cor-
relates well with amelioration of behavioral locomotor
deficiency. The anti-inflammatory effect of FLZ in the
MPTP model was due to reduced reactive microgliosis
elicited after MPTP treatment as evidenced by immuno-
histochemical analysis of activated microglia. The effec-
tiveness of FLZ in this animal study strongly confirms the
protective effect of FLZ, and the fact that this effect was
evident when FLZ was given 2 days after MPTP challenge
is an important consideration for the potential of FLZ for
clinical use in PD patients. Further, we measured MPP+
concentrations in the brains of mice from each group, and
found that FLZ didn't affect these MPP+ concentrations
(data not shown).
Conclusion
In summary, this study showed potent efficacy of FLZ in
protecting DA neurons against the neurotoxicity induced
by LPS and MPTP. This protective effect was related to
FLZ's effect in preventing over-activation of microglia. FLZ
inhibition of microglial activation and of ROS production
by inhibiting PHOX assembly underlay the FLZ-elicited
suppression of inflammatory factor production and
release by microglia. These findings, combined with the
fact that FLZ is a small molecule that can be taken orally
suggest that FLZ has potential as a new therapeutic com-
pound for treatment and prevention of chronic neurode-
generative diseases such as PD.
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